Trial Profile

A Phase 1b Multiple Ascending-dose Study of EQ001 in Subjects With Systemic Lupus Erythematosus With or Without Active Proliferative Lupus Nephritis

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 02 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Itolizumab (Primary) ; Methylprednisolone; Mycophenolate mofetil; Mycophenolic acid; Prednisone
Indications Lupus nephritis; Systemic lupus erythematosus
Focus Adverse reactions; Proof of concept
Acronyms EQUALISE
Sponsors Equillium

Most Recent Events

01 Apr 2024 Results (Type B Portion) presented in the Equillium Media Release.
25 Mar 2024 According to an Equillium media release, company expect to deliver the topline data to their partner Ono Pharmaceutical in the coming weeks. Ono Pharmaceutical option exercise decision for itolizumab expected in 2H 2024.
26 Feb 2024 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com